Atara Biotherapeutics Inc (NASDAQ:ATRA) CEO Isaac E. Ciechanover sold 28,700 shares of the stock in a transaction on Friday, January 12th. The stock was sold at an average price of $21.39, for a total transaction of $613,893.00. Following the completion of the sale, the chief executive officer now directly owns 743,675 shares of the company’s stock, valued at approximately $15,907,208.25. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.
Atara Biotherapeutics Inc (NASDAQ:ATRA) traded up $6.10 on Friday, reaching $28.25. 3,694,136 shares of the company were exchanged, compared to its average volume of 1,425,678. The firm has a market cap of $864.33, a price-to-earnings ratio of -8.14 and a beta of 1.27. Atara Biotherapeutics Inc has a 1-year low of $11.80 and a 1-year high of $30.40.
Atara Biotherapeutics (NASDAQ:ATRA) last released its quarterly earnings results on Thursday, November 9th. The biotechnology company reported ($1.02) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.97) by ($0.05). sell-side analysts anticipate that Atara Biotherapeutics Inc will post -4 earnings per share for the current year.
Several equities research analysts have recently issued reports on the stock. BidaskClub raised shares of Atara Biotherapeutics from a “hold” rating to a “buy” rating in a research report on Thursday. Citigroup raised shares of Atara Biotherapeutics from a “sell” rating to a “neutral” rating and set a $18.00 price objective for the company in a research report on Wednesday, January 3rd. ValuEngine raised shares of Atara Biotherapeutics from a “sell” rating to a “hold” rating in a research report on Friday, December 29th. Canaccord Genuity reissued a “buy” rating on shares of Atara Biotherapeutics in a research report on Friday, December 29th. Finally, Goldman Sachs Group reaffirmed a “neutral” rating and set a $20.00 price target on shares of Atara Biotherapeutics in a report on Friday, October 6th. Four investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. The company currently has an average rating of “Buy” and an average price target of $26.00.
TRADEMARK VIOLATION WARNING: This piece was published by Markets Daily and is the property of of Markets Daily. If you are reading this piece on another website, it was stolen and reposted in violation of U.S. & international copyright & trademark legislation. The legal version of this piece can be viewed at https://www.themarketsdaily.com/2018/01/13/atara-biotherapeutics-inc-atra-ceo-isaac-e-ciechanover-sells-28700-shares.html.
Atara Biotherapeutics Company Profile
Atara Biotherapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is focused on developing therapies for patients with severe and life-threatening diseases. The Company operates through the business of developing and commercializing therapeutics segment. The Company is focused on developing allogeneic or third-party derived antigen-specific T-cells.
Receive News & Ratings for Atara Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atara Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.